DA
Therapeutic Areas
NK:IO Pipeline
| Drug | Indication | Phase |
|---|---|---|
| wNK:IO Cells | Haematological and solid tumours | Preclinical |
| eNK:IO Cells | Hard-to-treat cancer subtypes | Preclinical |
| dNK:IO REV-ERB Antagonists | Cancer, long-term pathogen infection | Research |
| Drug | Indication | Phase |
|---|---|---|
| wNK:IO Cells | Haematological and solid tumours | Preclinical |
| eNK:IO Cells | Hard-to-treat cancer subtypes | Preclinical |
| dNK:IO REV-ERB Antagonists | Cancer, long-term pathogen infection | Research |